Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LG 631

Next Previous
Drug Profile

LG 631

Alternative Names: LG631; LG631-CD34; Stem cell therapy - Case Western Reserve University/Opus Bio

Latest Information Update: 13 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Case Western Reserve University
  • Developer Case Western Reserve University; Opus Bio
  • Class Chemoprotectants; Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference; MGMT protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No

Highest Development Phases

  • Suspended Chemotherapy-induced damage

Most Recent Events

  • 27 Jul 2015 Phase-I clinical trials in Chemotherapy induced damage in USA (Parenteral)
  • 14 Aug 2014 Lentigen Corporation starts operating as Opus Bio and gains certain rights to use lentiviral technology
  • 14 Aug 2014 Miltenyi Biotec acquires the cell and gene therapy assets of Lentigen Corporation, and forms Lentigen Technology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top